MY ACCOUNT | NEWSLETTER |

Use of intralipid emulsion therapy to treat oleander toxicosis in a domestic goose

To describe the case of a domestic goose treated with lipid emulsion following the ingestion of oleander leaves


To describe the case of a domestic goose treated with lipid emulsion following the ingestion of oleander leaves

Ingestion of toxic substances is a common event in companion animals and livestock, especially in waterfowl. Oleander (Nerium oleander) toxicosis is rarely reported in avian species, with symptoms including cardiac, neurological, and gastrointestinal manifestations.

A 6-month-old domestic goose (Anser anser domesticus) was presented for depression, anorexia, permanent sternal recumbency, weakness and incoordination, and the owners witnessed the ingestion of oleander leaves. Despite the absence of evident cardiac symptoms, biochemical, hematological findings showed a significant increase of CPK, AST, LDH, and troponin I. Therapy was set with intravenous (IV) fluid administration, antibiotic and anti-inflammatory, oral activated charcoal, and IV lipid emulsion at 15 mL/kg/h. Clinical improvement was achieved after 2 hours. The patient was discharged 3 days after admission, with complete recovery and return to normal biochemical values 10 days after initial presentation.

The present work describes a case of spontaneous oleander poisoning in a domestic goose, with the first use of troponin I to diagnose cardiac injury in this species and the first report of IV lipid emulsion to successfully treat this kind of toxicosis in veterinary practice.

“Use of intralipid emulsion therapy to treat oleander toxicosis in a domestic goose (Anser anser domesticus)” Emanuele Lubian, et al. Journal of Exotic Pet Medicine. https://doi.org/10.1053/j.jepm.2021.08.018

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

World Veterinary Dermatology Day

Like0
Dislike0

Artificial insemination market to grow to $3B by 2028

Like0
Dislike0

February is National Pet Dental Health Month

Like0
Dislike0

Falling markets? Don't panic, it's not the first time

Like0
Dislike0

Treatment of canine chronic cutaneous lupus erythematosus with oclacitinib

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2023 - All Rights Reserved
ISSN 2768-198X

Top